Goodwin Procter today announced the launch of Big Molecule Watch, a new firm blog that represents a first-of-its-kind resource for the biosimilars industry.
Big Molecule Watch will cover, in real time, updates and analyses on regulatory issues, litigation, legislation and other news in this rapidly developing area.
The blog also provides a host of resources for blog users. In addition to a primer on biologics, biosimilars and the Biologics Price Competition and Innovation Act, the blog includes reference links to guidance documents from the U.S. FDA and its international counterparts, as well as court documents from the first two biosimilars litigations to occur in the United States. The blog will be updated as new guidances, legislation and legal developments occur.
Now that the first biosimilar applications have been filed in the United States, and a number of biosimilars have been approved in highly-regulated markets such as the EU and Japan, there is great interest and excitement in the potential of biosimilars to transform the pharmaceutical industry.
The editors of Big Molecule Watch have collectively been watching and engaging with the world of biologics (“big molecules”) since before the inception of the biosimilars industry in the United States and are excited to have this new forum for sharing their observations on developments in the industry.
“We are pleased to offer industry watchers an efficient and timely way to keep informed about developments in this very dynamic field,” said Robert Cerwinski, an editor of Goodwin’s Big Molecule Watch blog.
Big Molecule Watch will be led by partners in Goodwin Procter’s IP Litigation and Life Sciences Groups who earlier this year published Biosimilars: A Guide to Regulatory and Intellectual Property Issues.
Please visit the Big Molecule Watch blog, available at www.bigmoleculewatch.com.